Goldman Sachs’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-390
| Closed | -$8.24K | – | 5955 |
|
|
2023
Q2 | $8.24K | Sell |
390
-8,418
| -96% | -$259K | ﹤0.01% | 5601 |
|
|
2023
Q1 | $237K | Buy |
8,808
+3,121
| +55% | +$145K | ﹤0.01% | 5225 |
|
|
2022
Q4 | $201K | Sell |
5,687
-1,040
| -15% | -$125K | ﹤0.01% | 5307 |
|
|
2022
Q3 | $1.52M | Sell |
6,727
-1,839
| -21% | -$452K | ﹤0.01% | 4201 |
|
|
2022
Q2 | $1.62M | Sell |
8,566
-437
| -5% | -$88.1K | ﹤0.01% | 4225 |
|
|
2022
Q1 | $2.24M | Sell |
9,003
-3,819
| -30% | -$604K | ﹤0.01% | 4160 |
|
|
2021
Q4 | $2M | Buy |
12,822
+123
| +1% | +$23.8K | ﹤0.01% | 4252 |
|
|
2021
Q3 | $2.54M | Sell |
12,699
-1,154
| -8% | -$274K | ﹤0.01% | 3963 |
|
|
2021
Q2 | $3.54M | Sell |
13,853
-3,088
| -18% | -$771K | ﹤0.01% | 3666 |
|
|
2021
Q1 | $4.5M | Sell |
16,941
-1,307
| -7% | -$412K | ﹤0.01% | 3226 |
|
|
2020
Q4 | $6.73M | Buy |
18,248
+3,826
| +27% | +$1.1M | ﹤0.01% | 2780 |
|
|
2020
Q3 | $3.52M | Buy |
14,422
+4,574
| +46% | +$1.42M | ﹤0.01% | 3157 |
|
|
2020
Q2 | $2.84M | Buy |
9,848
+7,842
| +391% | +$2.31M | ﹤0.01% | 3212 |
|
|
2020
Q1 | $409K | Sell |
2,006
-1,590
| -44% | -$507K | ﹤0.01% | 4324 |
|
|
2019
Q4 | $1.61M | Buy |
3,596
+228
| +7% | +$80.9K | ﹤0.01% | 3792 |
|
|
2019
Q3 | $1.04M | Buy |
3,368
+2,282
| +210% | +$741K | ﹤0.01% | 4006 |
|
|
2019
Q2 | $345K | Sell |
1,086
-1,105
| -50% | -$383K | ﹤0.01% | 4561 |
|
|
2019
Q1 | $919K | Buy |
2,191
+737
| +51% | +$296K | ﹤0.01% | 4106 |
|
|
2018
Q4 | $443K | Buy |
1,454
+1,094
| +304% | +$353K | ﹤0.01% | 4431 |
|
|
2018
Q3 | $130K | Sell |
360
-103
| -22% | -$35.2K | ﹤0.01% | 5057 |
|
|
2018
Q2 | $169K | Buy |
463
+69
| +18% | +$24.6K | ﹤0.01% | 5048 |
|
|
2018
Q1 | $116K | Buy |
+394
| New | +$116K | ﹤0.01% | 5225 |
|
|
2017
Q3 | – | Sell |
-1,148
| Closed | -$272K | – | 6916 |
|
|
2017
Q2 | $272K | Buy |
+1,148
| New | +$261K | ﹤0.01% | 5588 |
|
|
2016
Q1 | – | Sell |
-91
| Closed | -$60K | – | 7372 |
|
|
2015
Q4 | $60K | Buy |
91
+3
| +3% | +$1.7K | ﹤0.01% | 6449 |
|
|
2015
Q3 | $42K | Sell |
88
-37
| -30% | -$19.6K | ﹤0.01% | 6851 |
|
|
2015
Q2 | $71K | Buy |
125
+88
| +238% | +$244K | ﹤0.01% | 6758 |
|
|
2015
Q1 | $319K | Buy |
37
+5
| +16% | +$43.7K | ﹤0.01% | 5582 |
|
|
2014
Q4 | $279K | Buy |
+32
| New | +$186K | ﹤0.01% | 5860 |
|
|
2014
Q3 | – | Sell |
-30
| Closed | -$219K | – | 7303 |
|
|
2014
Q2 | $219K | Sell |
30
-45
| -60% | -$225K | ﹤0.01% | 6134 |
|
|
2014
Q1 | $403K | Buy |
+75
| New | +$354K | ﹤0.01% | 5470 |
|
Other funds holding EIGR
SAM
6CM
UOC
RC
GCP
Goldman Sachs's EIGR Position: Q3 2023 in Review
Goldman Sachs sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2023, closing a stake of 390 shares — an estimated $8.24K sold.
Goldman Sachs first reported a position in EIGR in Q1 2014 and held it in 30 quarters. The position peaked at $6.73M in Q4 2020. 51 funds tracked by Wall St. Rank hold EIGR as of Q3 2023.
- Goldman Sachs reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Goldman Sachs sold 390 Eiger BioPharmaceuticals, Inc. shares in Q3 2023, an estimated $8.24K.
- Goldman Sachs first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 30 quarters.
- Goldman Sachs's Eiger BioPharmaceuticals, Inc. position peaked at $6.73M in Q4 2020.
- 51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2023.
Based on Goldman Sachs's 13F filing for Q3 2023, filed 14 Nov 2023.